List of Excipients in Branded Drug SYFOVRE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Apellis Pharmaceuticals Inc	SYFOVRE	pegcetacoplan	73606-020	ACETIC ACID	2033-11-15
Apellis Pharmaceuticals Inc	SYFOVRE	pegcetacoplan	73606-020	SODIUM ACETATE	2033-11-15
Apellis Pharmaceuticals Inc	SYFOVRE	pegcetacoplan	73606-020	SODIUM HYDROXIDE	2033-11-15
Apellis Pharmaceuticals Inc	SYFOVRE	pegcetacoplan	73606-020	TREHALOSE DIHYDRATE	2033-11-15
Apellis Pharmaceuticals Inc	SYFOVRE	pegcetacoplan	73606-020	WATER	2033-11-15

# Syfovre Excipient Strategy and Commercial Opportunities in Geographic Atrophy

Last updated: August 29, 2026

Syfovre (pegcetacoplan) is a sterile, preservative-free intravitreal solution approved by the FDA on February 17, 2023, for geographic atrophy secondary to age-related macular degeneration. Its formulation uses a conventional ophthalmic injectable excipient system: phosphate buffering, sodium chloride for tonicity, polysorbate 20 for interfacial stabilization, and water for injection. The commercial opportunity lies less in novel excipient composition than in manufacturing reliability, low-particle control, prefilled delivery, storage optimization, and follow-on products that reduce injection burden. [1]

What is Syfovre and how is it administered?

Syfovre contains pegcetacoplan, a PEGylated C3 complement inhibitor. Each single-dose vial delivers 15 mg in 0.1 mL for intravitreal injection.

Attribute	Syfovre
Active ingredient	Pegcetacoplan
Pharmacologic class	Complement C3 inhibitor
Indication	Geographic atrophy secondary to age-related macular degeneration
FDA approval	February 17, 2023
Regulatory application	Biologics license application
Dose	15 mg/0.1 mL intravitreal injection
Administration interval	Every 25 days or every 60 days
Presentation	Preservative-free, single-dose vial
Route	Intravitreal
Manufacturer	Apellis Pharmaceuticals
Reference-product status	FDA-licensed biologic

Syfovre can be administered monthly or every other month. The dosing interval creates a commercial distinction from competing complement inhibitors and directly affects clinic capacity, injection revenue, drug acquisition, and patient adherence. The every-60-day regimen can reduce treatment visits, while monthly treatment may be selected when clinicians prioritize greater exposure to therapy. [1]

What excipients are used in Syfovre?

The Syfovre formulation contains the following inactive ingredients:

Excipient	Formulation role	Commercial significance
Sodium phosphate dibasic heptahydrate	Buffer component	Maintains formulation pH
Sodium phosphate monobasic monohydrate	Buffer component	Completes phosphate buffering system
Sodium chloride	Tonicity agent	Supports ocular tolerability and osmolality control
Polysorbate 20	Surfactant	Limits adsorption and aggregation at air-liquid and container interfaces
Water for injection	Vehicle	Provides sterile aqueous delivery medium

The FDA prescribing information identifies the product as a sterile solution with a pH of approximately 7.0. The formulation does not use a preservative, which is important for repeated intravitreal administration and single-dose ophthalmic packaging. [1]

Why is polysorbate 20 commercially important?

Polysorbate 20 is the most strategically significant excipient in the formulation. Pegcetacoplan is a large, PEGylated biologic that can be vulnerable to adsorption, agitation stress, and interfacial exposure during filling, shipping, and preparation for injection. A low concentration of polysorbate 20 can reduce surface-mediated loss and particle formation.

The principal manufacturing risks are:

• Polysorbate degradation during storage.
• Peroxide formation and oxidation-sensitive product impurities.
• Interaction with container surfaces or elastomeric components.
• Subvisible particle generation.
• Variability in raw-material quality.
• Potential impact on long-term potency and ocular tolerability.

This creates opportunities for high-purity polysorbate suppliers, low-peroxide grades, supplier qualification programs, and analytical testing platforms. Excipient vendors that can provide tighter control over fatty-acid composition, peroxide content, trace metals, and degradation products may obtain a higher-value position than commodity suppliers.

How does Syfovre’s excipient strategy support intravitreal safety?

The formulation is designed around a narrow safety margin. Intravitreal products are administered directly into the eye, so particulate matter, endotoxin, microbial contamination, pH drift, osmolality variation, and extractables can have direct clinical consequences.

The main formulation controls are:

1. Preservative-free packaging. Preservatives can cause ocular irritation and are generally unsuitable for repeated intraocular exposure.
2. Single-dose presentation. A single-use vial limits microbial risk after opening.
3. Near-physiologic tonicity. Sodium chloride supports tolerability in the vitreous environment.
4. Buffered pH. Phosphate salts help maintain chemical stability during shelf life.
5. Surfactant stabilization. Polysorbate 20 reduces protein and conjugate adsorption during manufacturing and handling.
6. Sterile filtration and container closure control. These steps are central to control of bioburden, endotoxin, and visible and subvisible particles.

The safety profile of Syfovre has been affected by retinal vasculitis and retinal vascular occlusion reports, including cases associated with severe vision loss. These events are not established as excipient-driven, but they increase the commercial value of formulation consistency, particulate control, container closure integrity, and administration-process controls. [1, 2]

What formulation patents protect Syfovre?

Syfovre is a biologic product, so its regulatory and patent framework differs from that of conventional small-molecule drugs. The FDA does not treat Syfovre as an ordinary Orange Book small-molecule product. The relevant reference-product and patent-dispute framework is associated with the Purple Book and the Biologics Price Competition and Innovation Act.

The commercially relevant protection layers include:

Protection layer	Relevance to Syfovre
Pegcetacoplan composition claims	Protect the active PEGylated C3 inhibitor
Complement-inhibition method claims	Cover treatment of geographic atrophy and related disorders
Formulation claims	May cover concentration, pH, buffer, surfactant, or stability parameters
Manufacturing claims	May cover conjugation, purification, PEGylation, or product-quality controls
Device and administration claims	May cover delivery configuration or dosing methods
Regulatory exclusivity	Limits approval of a biosimilar reference product for 12 years after first licensure

The public FDA label confirms the formulation composition but does not establish that every listed excipient combination is separately patented. Patent protection should therefore be evaluated at the claim level rather than inferred from the ingredient list. A competitor may be able to design around a formulation claim by changing the surfactant, buffer system, concentration, or container configuration while retaining the same active ingredient.

When does Syfovre lose regulatory exclusivity?

Syfovre received its first U.S. biologics license on February 17, 2023. Under the U.S. biologics framework, a biosimilar application generally cannot be approved until 12 years after first licensure of the reference product. This places the statutory reference-product exclusivity floor in February 2035, subject to the specific regulatory interpretation of first licensure and any applicable statutory exceptions. [3]

Milestone	Date
FDA approval	February 17, 2023
Earliest 12-year reference-product exclusivity endpoint	February 17, 2035
Earliest possible biosimilar approval based solely on 12-year exclusivity	February 17, 2035

Regulatory exclusivity does not eliminate patent risk. Patent claims could extend beyond 2035, while weak or narrow claims could permit a biosimilar sponsor to pursue approval with a non-infringement or invalidity position. Unlike a small molecule, Syfovre does not have a conventional Hatch-Waxman Paragraph IV pathway tied to Orange Book-listed patents.

What is the Orange Book status of Syfovre?

Syfovre is not an ordinary Orange Book-listed small-molecule product. It is licensed under a BLA and is evaluated within the biologics framework. Competitive entry is therefore more likely to involve a biosimilar or interchangeable-product strategy under section 351(k) of the Public Health Service Act than an abbreviated new drug application with Paragraph IV certification.

A biosimilar sponsor would need to address:

• Analytical similarity to pegcetacoplan.
• Comparative structural characterization of the PEG conjugate.
• Biological activity and complement C3 inhibition.
• Product-related impurities and aggregates.
• Immunogenicity.
• Sterility and particulate control.
• Intravitreal delivery performance.
• The scope of any patent claims identified through the biologics patent process.

Are biosimilar or generic challenges likely for Syfovre?

A traditional generic challenge is unlikely because pegcetacoplan is a complex biologic conjugate rather than a conventional chemically synthesized small molecule. A biosimilar challenge is technically possible but difficult.

The principal barriers include:

Molecular complexity

Pegcetacoplan combines a complement-binding peptide-based active component with polyethylene glycol modification. The degree and distribution of PEGylation, product-related variants, aggregation, and higher-order characteristics can complicate analytical matching.

Intravitreal delivery

The product must meet stringent requirements for sterility, particulate matter, container closure integrity, extractables, and injection performance. A biosimilar sponsor cannot rely only on systemic pharmacokinetic comparability.

Clinical and regulatory positioning

The sponsor may seek extrapolation into the approved geographic-atrophy indication, but the FDA will assess the totality of evidence. A highly similar product with a differentiated excipient or device system may still require extensive comparability work.

Patent and manufacturing barriers

The most defensible protection may not reside in the basic buffer system. It may reside in the active conjugate, manufacturing process, impurity profile, stability specification, and clinical dosing methods. These barriers can delay entry even after regulatory exclusivity expires.

How does Syfovre compare with Izervay?

Izervay, or avacincaptad pegol, is the principal approved commercial competitor in geographic atrophy. It received FDA approval in August 2023. Both products target the complement pathway, but they differ in molecular target, formulation, concentration, dosing, and commercial positioning.

Attribute	Syfovre	Izervay
Active ingredient	Pegcetacoplan	Avacincaptad pegol
Complement target	C3	C5
Sponsor	Apellis Pharmaceuticals	Astellas, following acquisition of Iveric Bio
FDA approval	February 2023	August 2023
Indication	Geographic atrophy	Geographic atrophy
Initial approved regimen	Every 25 or 60 days	Every 28 days
Dosage form	Preservative-free intravitreal solution	Preservative-free intravitreal injection
Principal commercial differentiation	Earlier launch and flexible dosing	Alternative complement mechanism

The excipient opportunity is competitive rather than product-specific. Suppliers that can support both complement inhibitors with low-particle, low-peroxide, sterile injectable excipient systems may gain scale across the geographic-atrophy market.

What commercial opportunities exist in Syfovre excipients?

The largest opportunities are in supply assurance, stability improvement, and administration efficiency.

High-purity polysorbate 20

Demand can expand for pharmaceutical-grade polysorbate 20 with controlled peroxide levels, consistent fatty-acid distribution, and validated compatibility with PEGylated biologics. Suppliers can differentiate through lot-release analytics, oxidation profiling, and long-term stability data.

Alternative surfactants

A future Syfovre life-cycle product could evaluate poloxamers, polysorbate 80, or other nonionic surfactants. Any replacement would require extensive comparability and ocular-safety work. A successful alternative could reduce oxidation risk or improve product stability, but it would also create regulatory and patent considerations.

Ready-to-use delivery systems

Prefilled syringes, dual-chamber systems, or integrated injection devices could reduce vial preparation, dose loss, and handling steps. The commercial value is substantial because ophthalmology practices bear labor and scheduling costs for every intravitreal injection.

Longer shelf life and temperature tolerance

A formulation that tolerates wider temperature excursions or supports longer refrigerated shelf life could reduce distribution losses. Excipient optimization, container closure improvements, and better cold-chain monitoring can support this opportunity.

Low-volume dose recovery

Because the administered volume is only 0.1 mL, dead volume in the syringe and needle can produce meaningful product loss. Low-dead-volume syringes and optimized transfer devices could improve dose recovery and reduce the effective cost per injection.

Compounding and clinic workflow controls

Preservative-free single-dose packaging limits reuse, but clinics still need efficient preparation, storage, and administration processes. Device manufacturers can compete on filter-needle integration, dose accuracy, user ergonomics, and reduction of vial-access steps.

What manufacturing and intellectual-property barriers affect Syfovre competitors?

The most material barriers are not the basic excipients. Sodium chloride, phosphate salts, and water for injection are widely available. Polysorbate 20 is also a standard pharmaceutical excipient. The defensible barriers are the combination of:

• PEGylated active-substance manufacturing.
• Control of conjugation heterogeneity.
• Removal of unconjugated and over-conjugated species.
• Control of aggregates and particles.
• Sterile filling at a 0.1 mL dose.
• Compatibility between formulation, vial, stopper, and syringe.
• Long-term stability of the PEGylated molecule.
• Reproducible intravitreal safety.
• Patent claims covering composition, use, process, or formulation.

A competitor that changes the excipient system may avoid a narrow formulation claim but still face active-ingredient and manufacturing patents. Conversely, a competitor using the same excipients does not necessarily infringe a patent unless the asserted claims require those excipients in the claimed proportions or conditions.

What generic launch scenarios exist for Syfovre?

The most plausible entry scenarios are:

1. Post-exclusivity biosimilar entry. A sponsor files under section 351(k), establishes analytical and clinical similarity, and launches after the applicable exclusivity and patent barriers.
2. Patent settlement. A biosimilar sponsor reaches a license or launch-date agreement with Apellis before the end of all relevant patent terms.
3. Formulation design-around. A competitor changes the surfactant, buffer, concentration, or container system while preserving the same active molecule.
4. Device-led differentiation. A follow-on product uses a prefilled or low-dead-volume system to compete on clinic economics.
5. Clinical substitution by a rival mechanism. Izervay or later complement-pathway products gain share without directly challenging Syfovre’s patents.

The commercial timing will depend on the interaction between biologic exclusivity, patent litigation, manufacturing readiness, and physician adoption. A formulation-only design-around is unlikely to be sufficient if composition or method-of-use claims remain enforceable.

How strong is the Syfovre excipient estate?

The excipient estate is strategically useful but probably less central than the active-substance and manufacturing estate. The formulation uses established excipients, which limits the ability to claim broad exclusivity over the ingredients themselves. Stronger protection would generally require claims directed to a specific combination of:

• Pegcetacoplan concentration.
• Defined pH range.
• Phosphate-buffer concentration.
• Polysorbate 20 concentration.
• Stability profile.
• Particle or aggregate limits.
• Container closure configuration.
• Intravitreal dosing method.

The commercial strength of such claims depends on whether competitors can change one formulation parameter without losing stability, safety, or manufacturability.

Key Takeaways

• Syfovre is a preservative-free, single-dose intravitreal biologic containing pegcetacoplan in a phosphate-buffered, sodium-chloride-toned solution with polysorbate 20.
• Polysorbate 20 quality, oxidation control, and compatibility with the PEGylated molecule are the most important excipient issues.
• The product’s first U.S. approval was February 17, 2023, creating a statutory 12-year reference-product exclusivity floor extending to February 2035.
• Syfovre is not primarily exposed to a conventional Orange Book Paragraph IV generic challenge.
• Biosimilar entry is technically possible but faces substantial analytical, manufacturing, sterility, and intravitreal-delivery barriers.
• The strongest commercial opportunities are high-purity excipients, ready-to-use delivery systems, low-dead-volume devices, improved cold-chain stability, and manufacturing analytics.
• Izervay is the principal approved competing product, but its different complement target creates product-level rather than direct excipient substitution competition.

FAQs

Does Syfovre contain preservatives?

No. Syfovre is supplied as a preservative-free, single-dose intravitreal product. [1]

Can polysorbate 20 be replaced in a Syfovre follow-on formulation?

Potentially, but a replacement would require analytical comparability, stability, sterility, ocular-safety, and regulatory support. It could also affect patent positioning.

Is Syfovre eligible for a conventional ANDA generic?

No conventional ANDA pathway is expected to apply because Syfovre is a BLA-licensed biologic. Follow-on competition would generally use the biosimilar framework.

What is the most valuable excipient opportunity for Syfovre suppliers?

High-purity, low-peroxide polysorbate 20 with strong lot-to-lot control is the clearest direct excipient opportunity. Device and filling technologies may offer greater total commercial value.

Does changing Syfovre’s excipients avoid all patent risk?

No. A design-around of a formulation claim would not necessarily avoid claims covering pegcetacoplan, PEGylation, manufacturing, treatment methods, or other product characteristics.

References

1. U.S. Food and Drug Administration. (2023). Syfovre (pegcetacoplan injection) prescribing information. Apellis Pharmaceuticals, Inc.

2. U.S. Food and Drug Administration. (2023). FDA alerts health care professionals of risks associated with Syfovre (pegcetacoplan injection). FDA Drug Safety Communication.

3. U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. https://purplebooksearch.fda.gov/

4. U.S. Food and Drug Administration. (2023). FDA approves first treatment for geographic atrophy secondary to age-related macular degeneration. FDA.

5. U.S. Food and Drug Administration. (2023). Izervay (avacincaptad pegol) prescribing information. Iveric Bio, Inc.